AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06319495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06319495 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: 1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT04629963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Evaluation and BPISF
Description: Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
Study NCT04629963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys, a fingerstick blood sample, EMAs, and a digital wearable device
Description: The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
Study NCT06627062 — intervention group
Intervention type: PROCEDURE
Intervention: moderate and severe subluxated lens extraction
Description: A double-strand polypropylene suture (9-0 or 8-0) was looped and tied to one end of the preloaded CTR, which was then implanted into the capsular bag. The needle was inserted through the main incision, traversed the anterior chamber, under the posterior iris, and exited 2.0 mm behind the limbus at the central zonular weakness. The CTR was secured to the sclera using the knotless Z-suture technique to center the capsular bag, allowing safe insertion of the intraocular lens (IOL).
Study NCT06705465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video conference
Description: video conference
Study NCT06741696 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical extraction
Description: saline irrigation at different temperatures
Study NCT06741696 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: saline irrigations
Description: saline irrigation done after 3rd molar surgery
Study NCT06743412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular music listening
Description: Regular listening of self-selected music sung in Italian language during the hospital stay and after discharge till the follow-up visit after 3 months.
Study NCT06740630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine co-administered intramuscularly.
Study NCT06740630 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine co-administered intramuscularly.
Study NCT06740630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV (pneumococcal conjugate vaccine) 13
Description: The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06740630 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV (pneumococcal conjugate vaccine) 13
Description: The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06740630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 20
Description: The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06741748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Warming Method
Description: This intervention involves thawing vitrified blastocysts using a simplified, one-step direct warming method. The blastocyst is placed in a pre-warmed embryo culture medium for approximately one minute, then transferred directly into the embryo culture medium within a time-lapse system until ready for uterine transfer. The total thawing process takes approximately three minutes, reducing the duration and complexity of the procedure compared to conventional methods.
Study NCT06741748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Multi-step Thawing Method
Description: This intervention involves thawing vitrified blastocysts using a standard, multi-step process. The procedure includes sequential exposure of the blastocyst to different thawing solutions containing varying concentrations of cryoprotectants, followed by its transfer into an embryo culture medium in a time-lapse system. The overall process takes approximately 10-30 minutes.
Study NCT06742918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was given to the Group IV which was 2 grams of glucose.
Study NCT06742918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given to the Group IV which was 2 grams of glucose.
Study NCT06742918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was given to the Group IV which was 2 grams of glucose.
Study NCT06741371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monocryl
Description: Closure of the uterine scar by monofilament suture material
Study NCT06743282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete baseline questionnaires.
Study NCT06743282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Senyo App
Description: Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.
Study NCT06743282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Senyo App
Description: Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.
Study NCT06743282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete monthly questionnaires.
Study NCT04247243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid testing
Description: Abbott ID NOW Strep A testing
Study NCT04247243 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reference testing
Description: Culture-based testing
Study NCT05804162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
Study NCT05804162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide Placebo
Description: Participants will receive cagrilintide placebo subcutaneously once weekly.
Study NCT05804162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Partcipants will receive a single dose of moxifloxacin orally.
Study NCT05804162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Partcipants will receive a single dose of moxifloxacin orally.
Study NCT05804162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Partcipants will receive a single dose of moxifloxacin orally.
Study NCT05170737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0217
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD.
Study NCT06138873 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular tachycardia ablation with no AI-guidance
Description: As described in arms descriptions
Study NCT05643690 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UriFind Bladder Cancer Assay
Description: The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
Study NCT05104723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELJANZ (tofacitinib)
Description: The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
Study NCT05569291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Coaching Program (ACP)
Description: A semiautomated tele coaching program (application installed on a smartphone device with real time feedback and motivational messages) and a step counter (Fitbit Charge 4) providing direct feedback on total daily number of steps, walking time, time in at least moderate PA and movement intensity during walking.
Study NCT05569291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Coaching Program (MCP)
Description: A telecoaching program using a step counter (Fitbit Charge 4) without this custom smartphone application but with the Fitbit application. This intervention will be more focused on weekly personal feedback from a coach by telephone.
Study NCT05329961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil9
Description: The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
Study NCT05402137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight stigma intervention
Description: Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
Study NCT06297122 — intervention group
Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file (electronic health record). The identification of eligible cases will be conducted through an examination of the hospital's electronic microbiology database. Subsequently, the complete hospital record(s) of each patient will be used to extract a pre-defined set of variables required for data analysis.
Study NCT05133440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radium dichloride
Description: Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
Study NCT05133440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium dichloride
Description: Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
Study NCT05133440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
Study NCT06627673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Primary Total Knee Arthroplasty with a PEEK femoral component
Study NCT05746104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Indocyanine Green (ICG) and Visualization of Tumor
Description: A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
Study NCT05201469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
Study NCT05201469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VIB4920
Description: Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
Study NCT06020638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
Study NCT06020638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
Study NCT05822414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
Study NCT05822414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
Study NCT06117579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Description of a typical session:~Session duration: between 12 and 20 minutes 3 cycles of 30 repetitions with 1 minute of break between each cycle. The patient should inhale as hard as possible against an inspiratory resistance generated by a valve device.
Study NCT06035224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
Description: AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
Study NCT03494127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of GEL BALL FITTED MODULAR CUSHION
Description: DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
Study NCT03494127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of SQUISHINS FITTED MODULAR CUSHION
Description: DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
Study NCT06561516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Red ginseng)
Description: Step 1. Confrim the inclusion and exclusion criteria to select participants and abtain informed consent before surgery.~Step 2. Before surgery, research nurses randomly assign patients to either the Red ginseng or Control group (single-blind study).~Step 3. Blood tests and stool samples following rectal enema are collected from all patients before surgery.~Step 4. Depending on the type of gastrointestinal cancer (stomach cancer, pancreatobiliary cancer, colorectal cancer), radical resection surgery is performed.~Step 5. From 1 to 4 months after surgery, a three months period is designated for the Red ginseng group to take red ginseng tablets as instructed, with compliance assessements included.~Step 6. Four months after surgery, blood tests and stool samples are collected from all patients.~Step 7. After obtaining samples from the final registered patients, we will commission a contracted institution to conduct microbiome analysis test.
Study NCT06561659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Condition
Description: Already described in the arm description
Study NCT06561659 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Control Condition
Description: Already described in the arm description
Study NCT02226432 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: - Postoperative Antagonistic Peripheral Magnetic Stimulation
Description: Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified
Study NCT02226432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: - Postoperative Antagonistic Peripheral Magnetic Stimulation
Description: Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified
Study NCT02226432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Peripheral Magnetic Stimulation
Description: Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)
Study NCT02226432 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesics
Description: Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
Study NCT02226432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesics
Description: Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
Study NCT06366048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the different definitions of PHLF according to 50-50 criteria and ISGLS criteria
Description: Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.